Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

A randomized trial of rosuvastatin in the prevention of venous thromboembolism.

Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM.

N Engl J Med. 2009 Apr 30;360(18):1851-61. doi: 10.1056/NEJMoa0900241. Epub 2009 Mar 29.

2.
3.

Statins for primary prevention of venous thromboembolism.

Li L, Zhang P, Tian JH, Yang K.

Cochrane Database Syst Rev. 2014 Dec 18;(12):CD008203. doi: 10.1002/14651858.CD008203.pub3. Review.

PMID:
25518837
4.

Statins for primary prevention of venous thromboembolism.

Li L, Sun T, Zhang P, Tian J, Yang K.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD008203. doi: 10.1002/14651858.CD008203.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;12:CD008203.

PMID:
22161421
5.

Efficacy and safety of rosuvastatin in the management of dyslipidemia.

Rubba P, Marotta G, Gentile M.

Vasc Health Risk Manag. 2009;5(1):343-52. Epub 2009 Apr 8. Review.

8.
9.

The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.

Kones R.

Ther Adv Cardiovasc Dis. 2009 Aug;3(4):309-15. doi: 10.1177/1753944709337056. Epub 2009 May 21. Review.

PMID:
19460829
10.

Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance?

Rizzo M, Berneis K, Spinas GA, Rini GB, Kapur NK.

Int J Clin Pract. 2009 Mar;63(3):478-85. doi: 10.1111/j.1742-1241.2008.01979.x. Review.

PMID:
19222633
11.

An update on the benefits and risks of rosuvastatin therapy.

Toth PP.

Postgrad Med. 2014 Mar;126(2):7-17. doi: 10.3810/pgm.2014.03.2736. Review.

PMID:
24685964
12.

The JUPITER trial: How will it change clinical practice?

Watson KE.

Rev Cardiovasc Med. 2009 Spring;10(2):91-6. Review.

PMID:
19593321
13.
14.

Anticoagulant effects of statins and their clinical implications.

Undas A, Brummel-Ziedins KE, Mann KG.

Thromb Haemost. 2014 Mar 3;111(3):392-400. doi: 10.1160/TH13-08-0720. Epub 2013 Nov 28. Review.

PMID:
24285296
15.

Statins, inflammation and deep vein thrombosis: a systematic review.

Rodriguez AL, Wojcik BM, Wrobleski SK, Myers DD Jr, Wakefield TW, Diaz JA.

J Thromb Thrombolysis. 2012 May;33(4):371-82. doi: 10.1007/s11239-012-0687-9. Review.

16.

Cardiovascular disease, statins and vitamin D.

Wilding PM.

Br J Nurs. 2012 Feb 23-Mar 7;21(4):214-20. Review.

PMID:
22398934
17.

Statins and prevention of venous thromboembolism: Myth or reality?

Gaertner S, Cordeanu EM, Nouri S, Mirea C, Stephan D.

Arch Cardiovasc Dis. 2016 Mar;109(3):216-22. doi: 10.1016/j.acvd.2015.11.007. Epub 2016 Jan 14. Review.

PMID:
26778087
18.

[What do have arterial and venous disease in common?].

Piťha J, Auzký O, Roztočil K.

Vnitr Lek. 2014 Nov;60(11):985-9. Review. Czech.

PMID:
25600046
19.

C-reactive protein and venous thromboembolism: causal or casual association?

Lippi G, Favaloro EJ, Montagnana M, Franchini M.

Clin Chem Lab Med. 2010 Dec;48(12):1693-701. doi: 10.1515/CCLM.2010.335. Epub 2010 Aug 13. Review.

PMID:
20704541
20.

The up-to-date management of venous thromboembolism.

Chakrabarti AM.

Clin Med (Lond). 2015 Aug;15(4):368-70. doi: 10.7861/clinmedicine.15-4-368. Review.

PMID:
26407387
Items per page

Supplemental Content

Write to the Help Desk